TLDR
- Vertex closed higher as its $10B Crinetics deal expanded its pipeline
- VRTX gained 0.29% to $529.59 after recovering from intraday weakness
- Crinetics adds PALSONIFY, an approved oral treatment for acromegaly
- Atumelnant gives Vertex a Phase 3 asset for rare adrenal disease
- Vertex will fund the Crinetics deal using cash, debt, and bridge financing
Vertex Pharmaceuticals (VRTX) shares moved to expand its rare disease business by agreeing to buy Crinetics Pharmaceuticals in a cash deal valued at about $10 billion. VRTX closed at $529.59, up 0.29%, after recovering from a sharp intraday dip. The deal adds an approved acromegaly drug and a late-stage endocrine disease candidate to Vertex’s pipeline.
Vertex Pharmaceuticals Incorporated, VRTX
Vertex Targets Rare Endocrine Disease Growth
Vertex will acquire all outstanding Crinetics shares for $85 each in cash. The companies expect the transaction to close in the third quarter of 2026. The deal still needs regulatory clearance and approval from Crinetics shareholders.
The acquisition gives Vertex access to PALSONIFY, Crinetics’ approved treatment for adults with acromegaly. The FDA approved the once-daily oral therapy in September 2025. The European Medicines Agency also approved the drug, while other regulators continue their reviews.
Acromegaly remains a rare and chronic hormonal disorder with limited treatment options. The condition often stems from a pituitary tumor that produces excess growth hormone. About 20,000 diagnosed patients live with acromegaly in the United States.
PALSONIFY Adds Commercial Momentum
PALSONIFY offers an oral alternative to injectable somatostatin analogues used in acromegaly care. Its profile gives Vertex a marketed rare disease product beyond its core cystic fibrosis franchise. Therefore, the deal strengthens Vertex’s push into specialty markets with clear medical demand.
Crinetics has reported early demand for PALSONIFY since launch. Prescribing activity has expanded, and reimbursement coverage has also improved. As a result, Vertex gains a drug with an active commercial base and global growth potential.
Vertex plans to use its rare disease commercial experience to support PALSONIFY’s broader rollout. The company already operates a global infrastructure for specialized medicines. That reach could help Crinetics’ therapy gain wider adoption across approved markets.
Atumelnant Expands Vertex’s Pipeline
The deal also adds atumelnant, Crinetics’ Phase 3 candidate for congenital adrenal hyperplasia. The once-daily oral drug targets the ACTH receptor. Classic CAH affects about 17,000 addressable patients in the United States.
CAH disrupts cortisol production and can drive excess androgen levels. Many patients rely on steroid therapy, but high doses can create long-term risks. In Phase 2 studies, atumelnant helped patients approach normal androgen levels with physiologic steroid replacement.
Vertex expects to fund the transaction with cash and debt. Bank of America and Morgan Stanley Senior Funding provided $4.5 billion in committed bridge financing. The acquisition adds marketed and late-stage assets as Vertex builds beyond cystic fibrosis.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
